6
Treatment
ROS1 First-line
Recommendation 5.1
➤ For patients with ROS1 rearrangement, a performance status of
0–2, previously untreated NSCLC, clinicians may offer crizotinib or
entrectinib (Moderate recommendation; IC-L).
Recommendation 5.2
➤ For patients with ROS1 rearrangement, a performance status of 0–2,
previously untreated NSCLC, clinicians may offer standard therapy
based on the ASCO/OH non-driver mutation guideline (Moderate
recommendation; IC-L).
Recommendation 5.3
➤ For patients with ROS1 rearrangement, a performance status of
0–2, previously untreated NSCLC, clinicians may offer ceritinib or
lorlatinib (Weak recommendation; IC-L).
ROS1 Second-line
Recommendation 6.1
➤ For patients with ROS1 rearrangement, a performance status of 0–2,
previously treated with ROS1-targeted therapy, clinicians should
offer standard therapy based on the ASCO/OH non-driver mutation
guideline (Moderate recommendation; IC-L).
Recommendation 6.2
➤ For patients with ROS1 rearrangement, a performance status of 0–2,
previously treated with non-targeted therapy first-line, clinicians may
offer crizotinib or entrectinib or ceritinib (Moderate recommendation;
IC-L).
BRAF First-line
Recommendation 7.1
➤ For patients with a BRAF V600E mutation, clinicians may
offer dabrafenib/trametinib as first-line treatment (Moderate
recommendation; IC-L).
Recommendation 7.2
➤ For patients with a BRAF V600E mutation, clinicians may offer
standard first-line therapy based on the ASCO/OH non-driver
mutation guideline (Moderate recommendation; IC-L).
